Related Experiment Video
Updated: Jul 10, 2026
07:17
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
Published on: May 9, 2018
8.0K
Comparing post-treatment urinary and colorectal procedures in prostate cancer patients using population-based linked
Tenaw Tiruye1,2, Alex Jay3, Braden Higgs4,5
1Allied Health and Human Performance, University of South Australia, Adelaide, Australia. tenaw.tiruye@unisa.edu.au.
International Urology and Nephrology
|December 10, 2024
Summary
Radical prostatectomy (RP) and external beam radiotherapy (EBRT) for prostate cancer lead to different rates of post-treatment urinary and colorectal procedures. RP patients had more urinary procedures, while EBRT patients had more colorectal procedures long-term.
Area of Science:
- Urology
- Oncology
- Health Services Research
Background:
- Radical prostatectomy (RP) and external beam radiotherapy (EBRT) are primary treatments for prostate cancer.
- Understanding post-treatment procedural complications is crucial for patient management.
Purpose of the Study:
- To compare the rates of urinary and colorectal procedures following radical prostatectomy (RP) versus external beam radiotherapy (EBRT) in men with prostate cancer.
Main Methods:
- A cohort of 16,271 South Australian men diagnosed with prostate cancer (2001-2021) was analyzed.
- Urinary and colorectal procedure data were extracted from hospital and Medicare records.
- Propensity-matched analyses were used to compare outcomes between RP and EBRT groups, adjusting for patient characteristics.
Main Results:
- At 1-year, crude rates for urinary procedures were higher in the RP group (258/1000 person-years) compared to EBRT (74/1000 person-years).
- RP patients had 21.2% more urinary procedures at 6 months and 16.3% more at 5 years compared to EBRT.
- Colorectal procedures were initially higher post-RP but lower from 1 year onwards (5.9% lower at 5 years).
Conclusions:
- Significant differences in post-treatment procedures exist between RP and EBRT, suggesting varying adverse effect profiles.
- These findings can inform treatment decisions for prostate cancer patients.
